Vertex Readies For Major Readouts, With Data Due Soon In Big Pain Market

Phase II LSR Results For Suzetrigine Due By Year End

Q3 revenue beat consensus and Vertex raised its guidance, but R&D progress was the main highlight across the cystic fibrosis, kidney disease, type 1 diabetes and, particularly, pain pipeline.

Vertex may win two new drug approvals in the US in January (Shutterstock)

Vertex Pharmaceuticals reported third quarter revenue that exceeded expectations and raised its full-year guidance as a result, which analysts described as a typical quarter for the company. What generated greater interest within Vertex’s Q3 report, however, were its research and development updates, with several late-stage milestones revealed, including highly anticipated progress within the company’s pain pipeline.

Key Takeaways

Vertex reported $2.77bn in Q3 product revenues, beating consensus of $2.69bn, and raised its 2024 revenue guidance to $10.8bn-$10.9bn from $10.65bn-$10.85bn.

The positive earnings report was overshadowed by the company’s R&D pipeline updates, particularly its pain programs, including suzetrigine, pending at the US FDA for acute pain.

Near-term readouts are expected in late 2024 for suzetrigine from a Phase II LSR pain study, in the first half of 2025 from a Phase I/II trial of an inhaled mRNA therapeutic for CF, and in 2025 for a second cell therapy for type 1 diabetes.

Boston-based Vertex reported after the stock market closed on 4 November that its commercial products delivered $2.77bn in Q3 revenue,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

J&J Delivers In Q2 Despite Stelara Drop, Raising Guidance

 

Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.

Stock Watch: Pharma Financial Forecasts Cannot Withstand Headwinds Forever

 
• By 

Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

More from Scrip

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.